CSL Seqirus Announces PBS Listing for neffy (Adrenaline Nasal Spray)
A new, needle-free option for anaphylaxis is set to become more accessible to Australians, with the adrenaline nasal spray neffy listed on the Pharmaceutical Benefits Scheme (PBS) from 1 July 2026.
What is neffy?
Neffy is an adrenaline nasal spray indicated for the emergency treatment of anaphylaxis in adults and children weighing 15 kg or more and aged four years and over.
The Urgent Need for Access
Anaphylaxis is a life-threatening allergic reaction requiring immediate treatment with adrenaline. Between 2015 and 2020, emergency department presentations for anaphylaxis in Australia increased by 51%, and hospitalisations rose by 35%. Previously, neffy was only available via private prescription.
What the PBS Listing Means
The PBS listing means neffy will now be subsidised for eligible patients, improving access to an alternative to traditional adrenaline auto-injectors.
Stakeholder Reactions
- Professor Connie Katelaris AM (NSW allergist): The PBS listing provides more patients access to neffy as a preferred device.
- Maria Said AM (Allergy & Anaphylaxis Australia): Reimbursement offers more choice and may reduce the burden of constant vigilance.
- Associate Professor Kristina Rueter (ASCIA): Clinical guidelines have been updated to include neffy.
- Claire Morgan (CSL Seqirus): The PBS listing improves access and choice for at-risk Australians.
Side Effects
Common side effects include headache, nasal discomfort, throat irritation, and feeling jittery.